[1] J.N. Campbell, R.A. Meyer, Mechanisms of neuropathic pain, Neuron 52 (1) (2006) 77–92.
[2] D. Bouhassira, et al., Prevalence of chronic pain with neuropathic characteristics in the general population, Pain 136 (3) (2008) 380–387.
[3] N. Torrance, et al., The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey, J. Pain 7 (4) (2006) 281–289.
[4] S. Mathieson, et al., Trial of pregabalin for acute and chronic sciatica, N. Engl. J. Med. 376 (12) (2017) 1111–1120.
[5] R.A. Moore, et al., Oral nonsteroidal anti-inflammatory drugs for neuropathic pain, Cochrane Database Syst. Rev. (10) (2015) Cd010902.
[6] R.H. Dworkin, et al., Pharmacologic management of neuropathic pain: evidence- based recommendations, Pain 132 (3) (2007) 237–251.
[7] D.E. Coyle, Partial peripheral nerve injury leads to activation of astroglia and mi- croglia which parallels the development of allodynic behavior, Glia 23 (1) (1998) 75–83.
[8] K. Inoue, M. Tsuda, Microglia and neuropathic pain, Glia 57 (14) (2009) 1469–1479.
[9] M. Maeda, et al., Nerve injury-activated microglia engulf myelinated axons in a P2Y12 signaling-dependent manner in the dorsal horn, Glia 58 (15) (2010) 1838–1846.
[10] M. Yasui, et al., A chronic fatigue syndrome model demonstrates mechanical allo- dynia and muscular hyperalgesia via spinal microglial activation, Glia 62 (9) (2014) 1407–1417.
[11] Y. Masuda, et al., Zonisamide: pharmacology and clinical efficacy in epilepsy, CNS Drug. Rev. 4 (4) (1998) 341–360.
[12] M. Murata, Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson’s disease, Curr. Pharm. Des. 10 (6) (2004) 687–693.
[13] M.M. Hossain, et al., The anti-parkinsonian drug zonisamide reduces neuroin- flammation: role of microglial Nav 1.6, Exp. Neurol. 308 (2018) 111–119.
[14] K. Ohno, et al., Repositioning again of zonisamide for nerve regeneration, Neural Regen. Res. 11 (4) (2016) 541–542.
[15] H. Yagi, et al., Zonisamide enhances neurite elongation of primary motor neurons and facilitates peripheral nerve regeneration in vitro and in a mouse model, PLoS One 10 (11) (2015) e0142786.
[16] N. Bektas, et al., Zonisamide: antihyperalgesic efficacy, the role of serotonergic receptors on efficacy in a rat model for painful diabetic neuropathy, Life Sci. 95 (1) (2014) 9–13.
[17] M. Tanabe, et al., Zonisamide suppresses pain symptoms of formalin-induced in- flammatory and streptozotocin-induced diabetic neuropathy, J. Pharmacol. Sci. 107(2) (2008) 213–220.
[18] Z. Seltzer, et al., A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury, Pain 43 (2) (1990) 205–218.
[19] M. Tanabe, et al., Centrally mediated antihyperalgesic and antiallodynic effects of zonisamide following partial nerve injury in the mouse, Naunyn Schmiedeberg’s Arch. Pharmacol. 372 (2) (2005) 107–114.
[20] S. Suzuki, et al., Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex, Epilepsy Res. 12 (1) (1992) 21–27.
[21] A. Mori, et al., The anticonvulsant zonisamide scavenges free radicals, Epilepsy Res. 30 (2) (1998) 153–158.
[22] Y. Noda, et al., Zonisamide inhibits nitric oxide synthase activity induced by N- methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus, Res. Commun. Mol. Pathol. Pharmacol. 105 (1–2) (1999) 23–33.
[23] S.H. Kim, J.M. Chung, An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat, Pain 50 (3) (1992) 355–363.
[24] M. Tsuda, et al., P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury, Nature 424 (6950) (2003) 778–783.
[25] T. Masuda, et al., IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype, Cell Rep. 1 (4) (2012) 334–340.
[26] T. Masuda, et al., Transcription factor IRF5 drives P2X4R+-reactive microglia gating neuropathic pain, Nat. Commun. 5 (2014) 3771.
[27] S. Kanbara, et al., Zonisamide ameliorates progression of cervical spondylotic myelopathy in a rat model, Sci. Rep. 10 (1) (2020) 13138.
[28] S.R. Chaplan, et al., Quantitative assessment of tactile allodynia in the rat paw, J. Neurosci. Methods 53 (1) (1994) 55–63.
[29] D.H. Vrinten, F.F. Hamers, ‘CatWalk’ automated quantitative gait analysis as a novel method to assess mechanical allodynia in the rat; a comparison with von Frey testing, Pain 102 (1–2) (2003) 203–209.
[30] M. Kobayashi, et al., A DAP12-dependent signal promotes pro-inflammatory po- larization in microglia following nerve injury and exacerbates degeneration of in- jured neurons, Glia 63 (6) (2015) 1073–1082.
[31] H. Konishi, et al., Annexin III implicated in the microglial response to motor nerve injury, Glia 53 (7) (2006) 723–732.
[32] Z. Yu, et al., Erianin inhibits high glucose-induced retinal angiogenesis via blocking ERK1/2-regulated HIF-1alpha-VEGF/VEGFR2 signaling pathway, Sci. Rep. 6 (2016) 34306.
[33] Q. Han, et al., 6-Shogaol attenuates LPS-induced inflammation in BV2 microglia cells by activating PPAR-γ, Oncotarget 8 (26) (2017) 42001–42006.
[34] C.U. Kloss, et al., Effect of lipopolysaccharide on the morphology and integrin immunoreactivity of ramified microglia in the mouse brain and in cell culture, Exp. Neurol. 168 (1) (2001) 32–46.
[35] W. Bi, et al., Rifampicin improves neuronal apoptosis in LPS-stimulated cocultured BV2 cells through inhibition of the TLR-4 pathway, Mol. Med. Rep. 10 (4) (2014) 1793–1799.
[36] W. Chen, et al., Immortalization and characterization of a nociceptive dorsal root ganglion sensory neuronal line, J. Peripher. Nerv. Syst. 12 (2) (2007) 121–130.
[37] A. Bhattacherjee, et al., Trophic factor and hormonal regulation of neurite out- growth in sensory neuron-like 50B11 cells, Neurosci. Lett. 558 (2014) 120–125.
[38] M. Tsuda, et al., Neuropathic pain and spinal microglia: a big problem from mo- lecules in “small” glia, Trends Neurosci. 28 (2) (2005) 101–107.
[39] M. Kobayashi, et al., TREM2/DAP12 signal elicits proinflammatory response in microglia and exacerbates neuropathic pain, J. Neurosci. 36 (43) (2016) 11138–11150.
[40] D.C. Wu, et al., NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine model of Parkinson’s disease, Proc. Natl. Acad. Sci. U. S. A. 100 (10) (2003) 6145–6150.
[41] B.M. Babior, NADPH oxidase: an update, Blood 93 (5) (1999) 1464–1476.
[42] K. Kobayashi, et al., Minocycline selectively inhibits M1 polarization of microglia, Cell Death Dis. 4 (3) (2013) e525–e.
[43] A. Henn, et al., The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation, Altex 26 (2) (2009) 83–94.
[44] K. Kohno, et al., Temporal kinetics of microgliosis in the spinal dorsal horn after peripheral nerve injury in rodents, Biol. Pharm. Bull. 41 (7) (2018) 1096–1102.
[45] M. Zhuo, et al., Neuronal and microglial mechanisms of neuropathic pain, Mol. Brain 4 (2011) 31.
[46] A. Sakaue, et al., Antinociceptive effects of sodium channel-blocking agents on acute pain in mice, J. Pharmacol. Sci. 95 (2) (2004) 181–188.
[47] A.J. Todd, A. Ribeiro-da-Silva, Anatomical Changes in the Spinal Dorsal Horn After Peripheral Nerve Injury//Zhuo M. Molecular Pain, Springer New York, New York, NY, 2007, pp. 309–324.
[48] S. Takaku, K. Sango, Zonisamide enhances neurite outgrowth from adult rat dorsal root ganglion neurons, but not proliferation or migration of Schwann cells, Histochem. Cell Biol. 153 (3) (2020) 177–184.